GSA Capital Partners LLP Boosts Stock Position in Moderna, Inc. $MRNA

GSA Capital Partners LLP boosted its stake in Moderna, Inc. (NASDAQ:MRNA) by 216.3% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 38,922 shares of the company’s stock after buying an additional 26,617 shares during the period. GSA Capital Partners LLP’s holdings in Moderna were worth $1,005,000 at the end of the most recent reporting period.

Other institutional investors have also recently made changes to their positions in the company. Norges Bank bought a new stake in shares of Moderna during the second quarter valued at approximately $94,910,000. Vanguard Group Inc. grew its position in shares of Moderna by 3.2% in the 2nd quarter. Vanguard Group Inc. now owns 41,708,705 shares of the company’s stock worth $1,150,743,000 after buying an additional 1,312,192 shares during the period. Legal Advantage Investments Inc. bought a new position in shares of Moderna in the 3rd quarter worth about $1,244,000. Letko Brosseau & Associates Inc. grew its position in Moderna by 2.4% during the 2nd quarter. Letko Brosseau & Associates Inc. now owns 918,190 shares of the company’s stock valued at $25,333,000 after purchasing an additional 21,765 shares during the last quarter. Finally, Mitsubishi UFJ Trust & Banking Corp bought a new position in shares of Moderna during the third quarter valued at $2,351,000. Institutional investors own 75.33% of the company’s stock.

Moderna Stock Up 6.7%

Shares of NASDAQ MRNA opened at $49.70 on Friday. The company has a current ratio of 3.29, a quick ratio of 3.22 and a debt-to-equity ratio of 0.07. Moderna, Inc. has a 12-month low of $22.28 and a 12-month high of $55.20. The firm’s 50-day moving average price is $38.61 and its 200-day moving average price is $30.29. The stock has a market capitalization of $19.42 billion, a price-to-earnings ratio of -6.84 and a beta of 1.32.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings data on Friday, February 13th. The company reported ($2.11) earnings per share for the quarter, topping the consensus estimate of ($2.79) by $0.68. The company had revenue of $678.00 million for the quarter, compared to analysts’ expectations of $611.14 million. Moderna had a negative return on equity of 30.15% and a negative net margin of 145.16%.The firm’s revenue for the quarter was down 33.2% on a year-over-year basis. During the same period in the previous year, the firm posted ($2.91) earnings per share. On average, equities research analysts anticipate that Moderna, Inc. will post -9.61 EPS for the current fiscal year.

Key Stories Impacting Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: FDA reverses course and will review Moderna’s mRNA flu vaccine (mRNA‑1010), with an Aug. 5, 2026 target date — this restores a clear pathway to potentially have a product available for the 2026‑27 season and is the main driver of today’s share strength. FDA agrees to review Moderna’s mRNA flu vaccine application in a reversal (CNBC)
• Positive Sentiment: Brokerage/analyst commentary is supportive — at least one note (Goldman Sachs referenced) expects upside for MRNA, which can amplify buying after the FDA news. Moderna (NASDAQ:MRNA) Stock Price Expected to Rise, The Goldman Sachs Group Analyst Says
• Neutral Sentiment: Moderna scheduled investor presentations at TD Cowen and Barclays in early March — provides management a forum to discuss regulatory progress, commercialization plans and financial outlook, but is informational rather than catalytic. Moderna to Present at Upcoming Conferences in March 2026
• Negative Sentiment: BioNTech filed a patent‑infringement suit against Moderna in Delaware, alleging Moderna’s COVID‑19 shot mNexspike infringes patents tied to BioNTech/Pfizer’s Comirnaty — this introduces potential damages, injunction risk and longer‑term legal overhang. BioNTech sues Moderna for patent infringement over COVID-19 shots (Reuters)
• Negative Sentiment: A court recently rejected two of Moderna’s defenses in a separate patent dispute with Arbutus, signaling increased legal exposure on mRNA‑related IP that could lead to further rulings or settlements. Court Rejects Two Moderna Defenses in mRNA Vaccine Patent Row With Arbutus

Analysts Set New Price Targets

MRNA has been the subject of a number of recent research reports. UBS Group restated a “neutral” rating and set a $36.00 price target on shares of Moderna in a research note on Monday. Wolfe Research restated an “underperform” rating and set a $17.00 target price on shares of Moderna in a research note on Thursday, November 20th. JPMorgan Chase & Co. lowered their price target on Moderna from $26.00 to $25.00 and set an “underweight” rating on the stock in a report on Thursday, October 23rd. BMO Capital Markets upgraded shares of Moderna from a “market perform” rating to a “buy” rating in a report on Monday, January 12th. Finally, Berenberg Bank set a $28.00 price target on shares of Moderna in a research note on Monday, November 17th. Two research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and five have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Reduce” and an average price target of $31.47.

Insider Transactions at Moderna

In other Moderna news, Director Noubar Afeyan sold 23,853 shares of the firm’s stock in a transaction on Thursday, December 11th. The stock was sold at an average price of $29.48, for a total transaction of $703,186.44. Following the transaction, the director directly owned 3,924 shares in the company, valued at $115,679.52. This trade represents a 85.87% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 10.90% of the stock is currently owned by company insiders.

Moderna Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.